Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prazosin Hydrochloride

FDA-approved product (capsule, oral), marketed as Minipress, Minipress Xl, Prazosin Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Prazosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prazosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prazosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

    NCT01323998 · start 2010-04

    Registered record
    Registry ID
    NCT01323998
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI; AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-06
    Enrolment
    35,032

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI; AB
    PhaseNot recorded
    Registry statusCompleted

  • Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans

    NCT01637584 · start 2010-04

    Registered record
    Registry ID
    NCT01637584
    Conditions
    Non PTSD; PTSD
    Interventions
    Prazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-04
    Completion
    2012-11
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon PTSD; PTSD
    InterventionPrazosin; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin

    NCT01178138 · start 2009-12

    Registered record
    Registry ID
    NCT01178138
    Conditions
    Continuous Methamphetamine Abuse
    Interventions
    Prazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-12
    Completion
    2013-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContinuous Methamphetamine Abuse
    InterventionPrazosin
    PhasePhase 2
    Registry statusCompleted

  • Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

    NCT01518972 · start 2009-09

    Registered record
    Registry ID
    NCT01518972
    Conditions
    Alcohol Abuse; Posttraumatic Stress Disorder
    Interventions
    Prazosin; Placebo medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09
    Completion
    2012-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Abuse; Posttraumatic Stress Disorder
    InterventionPrazosin; Placebo medication
    PhasePhase 2
    Registry statusCompleted

  • Optimum Treatment for Drug-Resistant Hypertension

    NCT02369081 · start 2009-05

    Registered record
    Registry ID
    NCT02369081
    Conditions
    Hypertension, Resistant to Conventional Therapy
    Interventions
    Spironolactone; Bisoprolol; Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-05
    Completion
    2015-08
    Enrolment
    348

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Resistant to Conventional Therapy
    InterventionSpironolactone; Bisoprolol; Doxazosin; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

    NCT00741585 · start 2008-09-01

    Registered record
    Registry ID
    NCT00741585
    Conditions
    Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    Interventions
    Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09-01
    Completion
    2018-06-30
    Enrolment
    21,983

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    InterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    PhasePhase 4
    Registry statusCompleted

  • Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation

    NCT00487032 · start 2008-05

    Registered record
    Registry ID
    NCT00487032
    Conditions
    Allergic Rhinitis; Tachyphylaxis; Rhinitis Medicamentosa
    Interventions
    Oxymetazoline 0.05% w/v; Fluticasone propionate 50 micrograms per actuation; Prazosin hydrochloride; Placebo to Prazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2009-05
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Tachyphylaxis; Rhinitis Medicamentosa
    InterventionOxymetazoline 0.05% w/v; Fluticasone propionate 50 micrograms per actuation; Prazosin hydrochloride; Placebo to Prazosin
    PhasePhase 4
    Registry statusCompleted

  • The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia

    NCT00687388 · start 2008-05

    Registered record
    Registry ID
    NCT00687388
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    selective alpha 1-blockers; celecoxib; alpha-blocker and NSAID
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    Interventionselective alpha 1-blockers; celecoxib; alpha-blocker and NSAID
    PhasePhase 4
    Registry statusWithdrawn

  • Study of the Medication Prazosin for Alcohol Dependence

    NCT00762710 · start 2008-01

    Registered record
    Registry ID
    NCT00762710
    Conditions
    Alcoholism
    Interventions
    Prazosin medication; Placebo medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2014-06
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcoholism
    InterventionPrazosin medication; Placebo medication
    PhasePhase 2
    Registry statusCompleted

  • Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

    NCT02266537 · start 2005-11

    Registered record
    Registry ID
    NCT02266537
    Conditions
    Healthy
    Interventions
    Tamsulosin; Alfuzosin; Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    Not recorded
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTamsulosin; Alfuzosin; Doxazosin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

    NCT00130156 · start 2005-10

    Registered record
    Registry ID
    NCT00130156
    Conditions
    High Blood Pressure
    Interventions
    Bunazosin; Doxazosin; Valsartin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-10
    Completion
    2009-03
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Blood Pressure
    InterventionBunazosin; Doxazosin; Valsartin
    PhasePhase 4
    Registry statusCompleted

  • Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

    NCT00563485 · start 2005-10

    Registered record
    Registry ID
    NCT00563485
    Conditions
    Prostatic Hyperplasia; Urinary Retention
    Interventions
    Doxazosin GITS (Cardura XL); Terazosin (Hytrin)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2005-10
    Completion
    2006-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia; Urinary Retention
    InterventionDoxazosin GITS (Cardura XL); Terazosin (Hytrin)
    PhaseNot applicable
    Registry statusTerminated

  • Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

    NCT00202449 · start 2004-07

    Registered record
    Registry ID
    NCT00202449
    Conditions
    Stress Disorders, Post-Traumatic; Sleep Disorders
    Interventions
    prazosin; paroxetine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2004-07
    Completion
    2008-02
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorders, Post-Traumatic; Sleep Disorders
    Interventionprazosin; paroxetine; Placebo
    PhaseNot applicable
    Registry statusTerminated

  • Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance

    NCT00108420 · start 2003-10

    Registered record
    Registry ID
    NCT00108420
    Conditions
    Stress Disorder, Post-Traumatic
    Interventions
    Prazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-10
    Completion
    2007-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorder, Post-Traumatic
    InterventionPrazosin
    PhasePhase 4
    Registry statusCompleted

  • Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

    NCT00183430 · start 2003-10

    Registered record
    Registry ID
    NCT00183430
    Conditions
    Post-Traumatic Stress Disorder; Sleep Initiation and Maintenance Disorders
    Interventions
    Prazosin; Placebo; Psychotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2003-10
    Completion
    2010-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Stress Disorder; Sleep Initiation and Maintenance Disorders
    InterventionPrazosin; Placebo; Psychotherapy
    PhaseNot applicable
    Registry statusTerminated